Skip to main content
×
×
Home

Anti-basal ganglia antibodies in primary obsessive–compulsive disorder: systematic review and meta-analysis

  • Daniel M. Pearlman (a1), Haily S. Vora (a2), Brian G. Marquis (a2), Souhel Najjar (a3) and Lauren A. Dudley (a4)...
Abstract
Background

Autoimmune-mediated basal ganglia dysfunction is implicated in the pathophysiology of neuropsychiatric disorders commonly manifesting with obsessive–compulsive features (e.g. Sydenham chorea). The relationship between autoimmunity and primary obsessive–compulsive disorder (OCD), however, is less clear.

Aims

To pool data on serum and cerebrospinal fluid (CSF) anti-basal ganglia antibody (ABGA) positivity in primary OCD (without neurological or autoimmune comorbidity) relative to controls or neuropsychiatric disorders previously associated with increased odds of ABGA positivity.

Method

We performed electronic database and hand-searches for studies meeting pre-specified eligibility criteria from which we extracted data using a standardised form. We calculated pooled estimates of ABGA positivity using a random-effects model.

Results

Seven case–control studies totalling 844 participants met the eligibility criteria. Meta-analysis showed that a significantly greater proportion of those with primary OCD were ABGA seropositive compared with various controls (odds ratio (OR) = 4.97, 95% CI 2.88–8.55, P<0.00001). This effect was not associated with heterogeneity or publication bias, and remained significant after stratifying the analysis by age, gender, disease severity, illness duration, immunostaining methodology, study quality, publication type, kind of control group, and sample size. There were no significant differences in ABGA seropositivity for comparisons between primary OCD and Tourette syndrome, attention-deficit hyperactivity disorder or paediatric acute-onset neuropsychiatric syndrome. Results of one study testing CSF samples showed that a significantly greater proportion of participants with primary OCD were ABGA CSF-positive compared with healthy controls (OR = 5.60, 95% CI 1.04–30.20, P = 0.045).

Conclusions

Odds of ABGA seropositivity are increased fivefold in primary OCD compared with controls, but are comparable to those associated with disorders previously associated with ABGA, providing circumstantial evidence of autoimmunity in a subset of those with primary OCD. Further experimental studies are needed to ascertain whether this relationship is causal.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Anti-basal ganglia antibodies in primary obsessive–compulsive disorder: systematic review and meta-analysis
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Anti-basal ganglia antibodies in primary obsessive–compulsive disorder: systematic review and meta-analysis
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Anti-basal ganglia antibodies in primary obsessive–compulsive disorder: systematic review and meta-analysis
      Available formats
      ×
Copyright
Corresponding author
Daniel M. Pearlman, MPH, Neuroinflammation Research Group, Epilepsy Center Division, Department of Neurology, NYU School of Medicine, 223 East 34th Street, New York, NY 10016, USA. Email: daniel.m.pearlman@gmail.com
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Mancebo, MC, Greenberg, B, Grant, JE, Pinto, A, Eisen, JL, Dyck, I, et al. Correlates of occupational disability in a clinical sample of obsessive–compulsive disorder. Compr Psychiatry 2008; 49: 4350.
2 Eisen, JL, Mancebo, MA, Pinto, A, Coles, ME, Pagano, ME, Stout, R, et al. Impact of obsessive–compulsive disorder on quality of life. Compr Psychiatry 2006; 47: 270–5.
3 Ayuso-Mateos, J. Global Burden of Obsessive–compulsive Disorder in the Year 2000. World Health Organization, 2006.
4 Ruscio, AM, Stein, DJ, Chiu, WT, Kessler, RC. The epidemiology of obsessive–compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 5363.
5 Williams, MT, Farris, SG, Turkheimer, E, Pinto, A, Ozanick, K, Franklin, ME, et al. Myth of the pure obsessional type in obsessive–compulsive disorder. Depress Anxiety 2011; 28: 495500.
6 Abramowitz, JS, Taylor, S, McKay, D. Obsessive–compulsive disorder. Lancet 2009; 374: 491–9.
7 Stein, DJ. Obsessive–compulsive disorder. Lancet 2002; 360: 397405.
8 Rachman, S. A cognitive theory of obsessions: elaborations. Behav Res Ther 1998; 36: 385401.
9 Rachman, S. A cognitive theory of obsessions. Behav Res Ther 1997; 35: 793802.
10 Maia, TV, Cooney, RE, Peterson, BS. The neural bases of obsessive–compulsive disorder in children and adults. Dev Psychopathol 2008; 20: 1251–83.
11 Welter, ML, Burbaud, P, Fernandez-Vidal, S, Bardinet, E, Coste, J, Piallat, B, et al. Basal ganglia dysfunction in OCD: subthalamic neuronal activity correlates with symptoms severity and predicts high-frequency stimulation efficacy. Transl Psychiatry 2011; 1: e5.
12 Modell, JG, Mountz, JM, Curtis, GC, Greden, JF. Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive–compulsive disorder. J Neuropsychiatry Clin Neurosci 1989; 1: 2736.
13 Baxter, LR, Schwartz, JM, Bergman, KS, Szuba, MP, Guze, BH, Mazziotta, JC, et al. Caudate glucose metabolic rate changes with both drug and behaviour therapy for obsessive–compulsive disorder. Arch Gen Psychiatry 1992; 49: 681–9.
14 Radua, J, van den Heuvel, OA, Surguladze, S, Mataix-Cols, D. Meta-analytical comparison of voxel-based morphometry studies in obsessive–compulsive disorder vs other anxiety disorders. Arch Gen Psychiatry 2010; 67: 701–11.
15 Chamberlain, SR, Menzies, L, Hampshire, A, Suckling, J, Fineberg, NA, del Campo, N, et al. Orbitofrontal dysfunction in patients with obsessive–compulsive disorder and their unaffected relatives. Science 2008; 321: 421–2.
16 Harrison, BJ, Soriano-Mas, C, Pujol, J, Ortiz, H, Lopez-Sola, M, Hernandez-Ribas, R, et al. Altered corticostriatal functional connectivity in obsessive–compulsive disorder. Arch Gen Psychiatry 2009; 66: 1189–200.
17 Pittenger, C, Bloch, MH, Williams, K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 2011; 132: 314–32.
18 Chakrabarty, K, Bhattacharyya, S, Christopher, R, Khanna, S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005; 30: 1735–40.
19 Rosenberg, DR, Benazon, NR, Gilbert, A, Sullivan, A, Moore, GJ. Thalamic volume in pediatric obsessive–compulsive disorder patients before and after cognitive behavioural therapy. Biol Psychiatry 2000; 48: 294300.
20 Hansen, ES, Hasselbalch, S, Law, I, Bolwig, TG. The caudate nucleus in obsessive–compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol 2002; 5: 110.
21 Stewart, SE, Mayerfeld, C, Arnold, PD, Crane, AJ, O'Dushlaine, C, Fagerness, JA, et al. Meta-analysis of association between obsessive–compulsive disorder and the 3’ region of neuronal glutamate transporter gene SLC1A1. Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 367–79.
22 Stewart, SE, Yu, D, Scharf, JM, Neale, BM, Fagerness, JA, Mathews, CA, et al. Genome-wide association study of obsessive–compulsive disorder. Mol Psychiatry 2013; 18: 788–98.
23 Wu, K, Hanna, GL, Rosenberg, DR, Arnold, PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive–compulsive disorder. Pharmacol Biochem Behav 2012; 100: 726–35.
24 Rotge, JY, Aouizerate, B, Tignol, J, Bioulac, B, Burbaud, P, Guehl, D. The glutamate-based genetic immune hypothesis in obsessive–compulsive disorder. An integrative approach from genes to symptoms. Neuroscience 2010; 165: 408–17.
25 Najjar, S, Pearlman, DM, Alper, K, Najjar, A, Devinsky, O. Neuroinflammation and psychiatric illness. J Neuroinflammation 2013; 10: 43.
26 Frick, LR, Williams, K, Pittenger, C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol 2013; 2013: 608–54.
27 Brimberg, L, Benhar, I, Mascaro-Blanco, A, Alvarez, K, Lotan, D, Winter, C, et al. Behavioural, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology 2013; 37: 2076–87.
28 Kirvan, CA, Cox, CJ, Swedo, SE, Cunningham, MW. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007; 178: 7412–21.
29 Kirvan, CA, Swedo, SE, Heuser, JS, Cunningham, MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9: 914–20.
30 Kirvan, CA, Swedo, SE, Snider, LA, Cunningham, MW. Antibody-mediated neuronal cell signaling in behaviour and movement disorders. J Neuroimmunol 2006; 179: 173–9.
31 Cunningham, MW. Streptococcus and rheumatic fever. Curr Opin Rheumatol 2012; 24: 408–16.
32 Swedo, SE, Leonard, HL, Rapoport, JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. Pediatrics 2004; 113: 907–11.
33 Swedo, SE, Leonard, HL, Garvey, M, Mittleman, B, Allen, AJ, Perlmutter, , et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155: 264–71.
34 Singer, HS, Giuliano, JD, Hansen, BH, Hallett, JJ, Laurino, JP, Benson, M, et al. Antibodies against human putamen in children with Tourette syndrome. Neurology 1998; 50: 1618–24.
35 Kansy, JW, Katsovich, L, McIver, KS, Pick, J, Zabriskie, JB, Lombroso, PJ, et al. Identification of pyruvate kinase as an antigen associated with Tourette syndrome. J Neuroimmunol 2006; 181: 165–76.
36 Fibbe, LA, Cath, DC, van den Heuvel, OA, Veltman, DJ, Tijssen, MA, van Balkom, AJ. Relationship between movement disorders and obsessive–compulsive disorder: beyond the obsessive–compulsive-tic phenotype. A systematic review. J Neurol Neurosurg Psychiatry 2012; 83: 646–54.
37 Hounie, AG, Pauls, DL, Mercadante, MT, Rosario-Campos, MC, Shavitt, RD, de Mathis, MA, et al. Obsessive–compulsive spectrum disorders in rheumatic fever with and without Sydenham's chorea. J Clin Psychiatry 2004; 65: 994–9.
38 Maia, DP, Teixeira, AL Jr, Quintao Cunningham, MC, Cardoso, F. Obsessive compulsive behaviour, hyperactivity, and attention deficit disorder in Sydenham chorea. Neurology 2005; 64: 1799–801.
39 Mercadante, MT, Diniz, JB, Hounie, AG, Ferrao, Y, Alvarenga, P, Brotto, S, et al. Obsessive–compulsive spectrum disorders in rheumatic fever patients. J Neuropsychiatry Clin Neurosci 2005; 17: 544–7.
40 Asbahr, FR, Garvey, MA, Snider, LA, Zanetta, DM, Elkis, H, Swedo, SE. Obsessive–compulsive symptoms among patients with Sydenham chorea. Biol Psychiatry 2005; 57: 1073–6.
41 Swedo, SE, Leonard, HL, Casey, BJ, Mannheim, GB, Lenane, MC, Rettew, DC, et al. Sydenham's chorea: physical and psychological symptoms of St Vitus dance. Pediatrics 1993; 91: 706–13.
42 Martino, D, Church, A, Giovannoni, G. Are antibasal ganglia antibodies important, and clinically useful? Pract Neurol 2007; 7: 3241.
43 Kirvan, CA, Swedo, SE, Kurahara, D, Cunningham, MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea. Autoimmunity 2006; 39: 21–9.
44 Dale, RC, Brilot, F. Autoimmune basal ganglia disorders. J Child Neurol 2012; 27: 1470–81.
45 Dale, RC, Church, AJ, Surtees, RA, Lees, AJ, Adock, JE, Harding, B, et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004; 127: 2133.
46 Sanchez-Carpintero, R, Albesa, SA, Crespo, N, Villoslada, P, Narbona, J. A preliminary study of the frequency of anti-basal ganglia antibodies and streptococcal infection in attention deficit/hyperactivity disorder. J Neurol 2009; 256: 1103–8.
47 Yaddanapudi, K, Hornig, M, Serge, R, De Miranda, J, Baghban, A, Villar, G, et al. Passive transfer of streptococcus-induced antibodies reproduces behavioural disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. Mol Psychiatry 2010; 15: 712–26.
48 Dale, RC, Merheb, V, Pillai, S, Wang, D, Cantrill, L, Murphy, TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012; 135: 3453–68.
49 Dale, RC, Candler, PM, Church, AJ, Wait, R, Pocock, JM, Giovannoni, G. Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 2006; 172: 187–97.
50 Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–9, W264.
51 Stroup, DF, Berlin, JA, Morton, SC, Olkin, I, Wilkinson, GD, Rennie, D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12.
52 Wells, G, Shea, B, O'Connell, D, Peterson, J, Welch, V, Losos, M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Presented at the 3rd Symposium on Systematic Reviews: Beyond the Basics, 3–5 July 2000 (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
53 Fritschy, JM. Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry. Eur J Neurosci 2008; 28: 2365–70.
54 Church, AJ, Dale, RC, Giovannoni, G. Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child 2004; 89: 611–4.
55 DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88.
56 Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60.
57 Egger, M, Davey Smith, G, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
58 Harbord, RM, Higgins, JPT. Meta-regression in Stata. Stata J 2008; 8: 493519.
59 Goodman, WK, Price, LH, Rasmussen, SA, Mazure, C, Fleischmann, RL, Hill, CL, et al. The Yale–Brown Obsessive–Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006–11.
60 Kawikova, I, Grady, BPX, Tobiasova, Z, Zhang, Y, Vojdani, A, Katsovich, L, et al. Children with Tourette's syndrome may suffer immunoglobulin A dysgammaglobulinemia: preliminary report. Biol Psychiatry 2010; 67: 679–83.
61 Singer, H, Gause, C, Grados, M. Antineuronal antibodies in obsessive–compulsive disorder: Comparisons in children with OCD-only, OCD + chronic TICS and OCD + PANDAS. Eur Psychiatry 2009; 24: S175.
62 Zuccolo, A, Mascaro-Blanco, A, Alvarez, K, Stoner, J, Cunningham, M. Antineuronal antibodies in a heterogeneous ‘PANDAS’ group with tics and obsessive compulsive disorder. Dev Med Child Neurol 2012; 54: 141.
63 Murphy, T, Storch, E. The relationship between streptococcal antibodies and the course of OCD and tics in a pediatric population. Eur Psychiatry 2009; 24: S177.
64 Swedo, SE, Kilpatrick, K, Shapiro, MB, Mannheim, G, Leonard, H. Antineuronal antibodies (AnA) in Sydenham's Chorea (SC) and obsessive–compulsive disorder (OCD) [abstract]. Pediatr Res 1991; 29: 364A.
65 Nicholson, TRJ, Ferdinando, S, Krishnaiah, RB, Anhoury, S, Lennox, BR, Mataix-Cols, D, et al. Prevalence of anti-basal ganglia antibodies in adult obsessive–compulsive disorder: cross-sectional study. Br J Psychiatry 2012; 200: 381–6.
66 Gause, C, Morris, C, Vernekar, S, Pardo-Villamizar, C, Grados, MA, Singer, HS. Antineuronal antibodies in OCD: comparisons in children with OCD-only, OCD+chronic tics and OCD+PANDAS. J Neuroimmunol 2009; 214: 118–24.
67 Maina, G, Albert, U, Bogetto, F, Borghese, C, Cat Berro, A, Mutani, R, et al. Anti-brain antibodies in adult patients with obsessive–compulsive disorder. J Affect Disord 2009; 116: 192200.
68 Bhattacharyya, S, Khanna, S, Chakrabarty, K, Mahadevan, A, Christopher, R, Shankar, SK. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive–compulsive disorder. Neuropsychopharmacology 2009; 34: 2489–96.
69 Morer, A, Lazaro, L, Sabater, L, Massana, J, Castro, J, Graus, F. Antineuronal antibodies in a group of children with obsessive–compulsive disorder and Tourette syndrome. J Psychiatr Res 2008; 42: 64–8.
70 Dale, RC, Heyman, I, Giovannoni, G, Church, AWJ. Incidence of anti-brain antibodies in children with obsessive–compulsive disorder. Br J Psychiatry 2005; 187: 314–9.
71 Trucco, M, Leckman, JF, Lombroso, PJ. Autoantibodies and HLA-DR antigens in patients with TS, OCD and ADHD [abstract]. Presentation 580.24, Society for Neuroscience Annual Meeting 2000, New Orleans (available at http://www.sfn.org/Annual-Meeting/Past-and-Future-Annual-Meetings/Abstract-Archive).
72 Rose, NR, Bona, C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14: 426–30.
73 Witebsky, E, Rose, NR, Terplan, K, Paine, JR, Egan, RW. Chronic thyroiditis and autoimmunization. JAMA 1957; 164: 1439–47.
74 Fluitman, S, Denys, D, Vulink, N, Schutters, S, Heijnen, C, Westenberg, H. Lipopolysaccharide-induced cytokine production in obsessive–compulsive disorder and generalized social anxiety disorder. Psychiatry Res 2010; 178: 313–6.
75 Fluitman, SB, Denys, DA, Heijnen, CJ, Westenberg, HG. Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive–compulsive disorder. Psychoneuroendocrinology 2010; 35: 906–11.
76 Poe, LB. Radiological cases of the month. Gastrointestinal manifestations of hemolytic uremic syndrome. Am J Dis Child 1989; 143: 1481–2.
77 Rippel, CA, Hong, JJ, Yoon, DY, Williams, PN, Singer, HS. Methodologic factors affect the measurement of anti-basal ganglia antibodies. Ann Clin Lab Sci 2005; 35: 121–30.
78 Morshed, SA, Parveen, S, Leckman, JF, Mercadante, MT, Bittencourt Kiss, MH, Miguel, EC, et al. Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette's syndrome, Sydenham's chorea, and autoimmune disorders. Biol Psychiatry 2001; 50: 566–77.
79 Dickerson, F, Stallings, C, Vaughan, C, Origoni, A, Khushalani, S, Yolken, R. Antibodies to the glutamate receptor in mania. Bipolar Disord 2012; 14: 547–53.
80 Dalmau, J, Gleichman, AJ, Hughes, EG, Rossi, JE, Peng, X, Meizan, L, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 27: 1091–8.
81 Irani, SR, Bera, K, Waters, P, Zulliani, L, Maxwell, S, Zandi, MS, et al. N-methyl-Daspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655–67.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×
Type Description Title
PDF
Supplementary materials

Pearlman et al. supplementary material
Supplementary Material

 PDF (96 KB)
96 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 38 *
Loading metrics...

Abstract views

Total abstract views: 106 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 21st April 2018. This data will be updated every 24 hours.

Anti-basal ganglia antibodies in primary obsessive–compulsive disorder: systematic review and meta-analysis

  • Daniel M. Pearlman (a1), Haily S. Vora (a2), Brian G. Marquis (a2), Souhel Najjar (a3) and Lauren A. Dudley (a4)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *